Abstract
Three human cell lines derived from Ewing's sarcoma (RM-82, VH-64, and WE-68) were investigated to establish the influence of recombinant human interferon γ (rhIFNγ) and tumour necrosis factor α (rhTNFα) on cell proliferation and survival and to characterize IFNγ and TNFα receptor expression. Incorporation of [3H]thymidine into cells was inhibited by rhIFNγ after 24 h of incubation. Half-maximal inhibition was observed with 10–80 U/ml rhIFNγ. A maximal effect (50%–70% inhibition of cell proliferation) was achieved by treatment of cells with 250 U/ml rhIFNγ. The influence of rhTNFα on proliferation was found to differ among cell lines and varied with the concentration and the duration of exposure of cells to this cytokine. In WE-68 and VH-64 cells [3H]thymidine incorporation was not affected by rhTNFα up to 2000 U/ml after 96 h of incubation, where-as in RM-82 cells the incorporation was inhibited by 35% after 48 h of incubation with 100 U/ml rhTNFα. However, all cell lines showed a synergistic antiproliferative response to the combination of rhIFNγ and rhTNFα after 24 h of incubation. The human recombinant cytokines interleukin(IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-6 and granulocyte/macrophagecolony-stimulating factor, tested alone and in combination with rhIFNγ and rhTNFα, had no influence on cell proliferation. Binding studies in the cell lines with125I-rhIFNγ revealed a dissociation constant (K d ) of 160–306 pM and approximately 8000–13500 receptors/cell. Binding experiments with125I-rhTNFα indicated 430–1250 receptors/cell withK d ranging from 13 pM to 162 pM. These data indicate that, among various cytokines, only IFN and TNFα are capable of potently reducing Ewing's sarcoma cell growth in vitro. Our data suggest that IFN alone or in combination with TNFα may be useful in the design of novel strategies in Ewing's sarcoma therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aggarwal BB, Eessalu TE, Hass PE (1985) Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature 318:665–667
Anderson P, Yip YK, Vilcek J (1982) Specific binding of125I-human interferon-γ to high affinity receptors on human fibroblasts. J Biol Chem 257:11301–11304
Baglioni C, McCandless S, Tavernier J, Fiers W (1985) Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem 260:13395–13397
Blalock JE, Georgiades JA, Langford NF, Johnson HM (1980) Purified human immune interferon has more potent anti-cellular activity than fibroblast or leukocyte interferon. Cell Immunol 49:390–394
Carlo-Stella C, Cazzola M, Ganser A (1988) Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hemapoietic progenitor cells (CFU-GEMM; CFU-MK, BFU-E and CFU-GM). Blood 72:1293–1299
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975a) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–3670
Carswell EA, Green S, Everson TC, Nathanson T, Biedler JL, Helson L, Spengler BA (1975b) Effect of tumor necrosis factor on cultured human melanoma cells. Nature 258:731–732
Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fischer RI (1989) Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 143:4282–4286
Fransen LF, Vanderheyden J, Ruysschaert R, Fiers W (1986) Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22:419–426
Ishii Y, Tsukagoshi S (1988) Specific binding of interferon-gamma and alpha2a to tumor cells and their antitumor activities. J Pharmacobiodyn 11:465–471
Jürgens H, Winkler K, Göbel U (1992) Bone tumours. In: Plowman PN, Pinkerton CR (eds) Paediatric oncology: clinical practice and controversies, Chapman and Hall Medical, London New York Tokyo, pp 325–350
Koper JW, Zwarthoff EC, Hagemeyer A, Braakman R, Avezaat CJJ, Bergstrom M, Lamberts SWJ (1991) Inhibition of the growth of cultured human meningioma cells by recombinant interferon-α. Eur J Cancer 27:416–419
Kull FC Jr, Jacobs S, Cuatrecasas P (1985) Cellular receptor for125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci USA 82:5756–5760
Lee DH, Aggarwal BB, Rinderknecht E, Assisi F, Chiu H (1984) The synergistic anti-proliferative effect of γ-interferon and human lymphotoxin. J Immunol 133:1083–1086
Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G, Dapunt O (1989) Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 9:461–468
Merlin G, Falcoff E, Aguet M (1985)125I-labelled human interferons alpha, beta and gamma: comparative receptor binding data. J Gen Virol 66:1149–1152
Miller SC, Ito H, Torti FM (1988) Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol 8:2295–2301
Morikawa K, Morikawa R, Killion JJ, Fan D, Fidler IJ (1990) Isolation of human colon carcinoma cells for resistance to a single interferon associated with cross-resistance to multiple recombinant interferons: alpha, beta and gamma. JNCI 82:517–522
Mortarini R, Belli F, Parmiani G, Anichini A (1990) Cytokine-mediated modulation of HLA-Class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1β, rTNF-α, rIFN-γ, rIL4 and their combinations. Int J Cancer 45:334–341
Nagao S, Sato K, Osada Y (1986) Binding of human γ-interferon to human epidermal tumor cells with different susceptibilities. Cancer Res 46:3279–3282
Pfizenmaier K, Scheurich P, Schlutter C, Kronke M (1987) Tumor necrosis factor enhance HLA-A, B, C and HLA-DR gene expression in human tumor cells. J Immunol 138:975–980
Rothlein R, Czajkowski M, O'Neill MM, Marlin SD, Mainolfi E, Merluzzi VJ (1988) Induction of intercellular adhesion molecule 1 on primary and continous cell lines by pro-inflammatory cytokines. J Immunol 141:1665–1669
Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA, Old LJ (1985) High affinity binding of125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors. J Exp Med 162:1099–1104
Ruggiero V, Tavernier J, Fiers W, Baglioni C (1986) Induction of the synthesis of tumor necrosis factor receptors by interferon-γ. J Immunol 136:2445–2450
Sarkar FH, Gupta SL (1984) Interferon receptor interaction. Internalization of interferon α2 and modulation of its receptor on human cells. Eur J Biochem 140:461–467
Schiller JH, Biiner G, Storer B, Wilson JKV (1987) Synergistic antitumor effects of tumor necrosis factor and γ-interferon on human colon carcinoma cell lines. Cancer Res 47:2809–2813
Sen GC, Lengyel P (1992) The interferon system: a bird's eye view of its biochemistry. J Biol Chem 267:5017–5020
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shephard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230:943–945
Takeda K, Iwamoto S, Sugimoto H, Takuma T, Kawatani N, Noda M, Morise H, Arimura H, Konno K (1986) Identity of differentiation inducing factor and tumour necrosis factor. Nature 323:338–340
Trinchieri G, Perussia B (1985) Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6:131–136
Tsujimoto M, Yip YK, Vilcek J (1986) Interferon-γ enhances the expression of cellular receptors for tumor necrosis factor. J Immunol 136:2442–2444
Ucer U, Bartsch H, Scheurich P, Berkovic D, Ertel C, Pfizenmaier K (1986) Qantitation and characterization of γ-interferon receptors on human tumor cells. Cancer Res 46:5339–5343
van Valen F, Jürgens H, Winkelmann W, Keck E (1989) Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68. Cell Signal 1:435–446
van Valen F, Hanenberg H, Fried C, Bott U, Burdach S, Winkelmann W, Jürgens H, Göbel U (1991) Interferon-γ and tumor necrosis factor-α induce adhesion molecule ICAM-1 and HLA class I antigen expression in Ewing sarcoma cells. Med Pediatr Oncol 19:342
van Valen F, Winkelmann W, Jürgens H (1992a) Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J Cancer Res Clin Oncol 118:269–275
van Valen F, Winkelmann W, Jürgens H (1992b) Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines. J Cancer Res Clin Oncol 118:529–536
Vietti TJ, Gehan EA, Nesbit ME, Burgert EO, Pilepich M, Tefft M, Kissane J, Pritchard D (1981) Multimodal therapy in metastatic Ewing's sarcoma: an intergroup study. NCI Monogr 56:279–284
Vilcek J, Palombella VJ, Hendriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163:632–643
Wilkins RM, Pritchard DJ, Burgert EO, Unni KK (1986) Ewing's sarcoma of bone: experience with 140 patients. Cancer 58:2551–2555
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Valen, F., Winkelmann, W., Burdach, S. et al. Interferonγ and tumour necrosis factorα induce a synergistic antiproliferative response in human Ewing's sarcoma cells in vitro. J Cancer Res Clin Oncol 119, 615–621 (1993). https://doi.org/10.1007/BF01372725
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01372725